ImmunoGen Announces Top-Line Results From Pivotal SORAYA Trial Of Mirvetuximab Soravtansine In Ovarian Cancer; Trial Met Primary Endpoint With Confirmed Objective Response Rate Of 32.4%

by | Nov 30, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.